Leopoldina-Krankenhaus der Stadt Schweinfurt GmbH
- Address
- lock Available on a paid plan
Digestive System Diseases
The Oncology unit at Leopoldina‑Krankenhaus der Stadt Schweinfurt is conducting a series of studies on gastrointestinal malignancies, seeking to assess innovative targeted therapies and immunotherapy regimens that could extend patient overall survival and reduce disease recurrence.
- Colon and colorectal cancer
- Gastric adenocarcinoma and gastro‑esophageal junction cancer
- Esophageal adenocarcinoma
- KRAS‑mutated colorectal adenocarcinoma
- MSS/pMMR metastatic colorectal cancer
These trials emphasize personalized treatment selection, incorporate quality‑of‑life assessments, and aim to bring new therapeutic options to patients across the region.
Female Urogenital Diseases and Pregnancy Complications
In the realm of female cancers, the site focuses on breast and ovarian malignancies, evaluating novel combinations such as HER2‑directed agents, CDK‑4/6 inhibitors, and immune checkpoint inhibitors to improve cure rates for early and advanced disease.
- Early HER2‑positive breast cancer
- Triple‑negative breast cancer
- Hormone‑receptor‑positive, HER2‑negative breast cancer
- High‑grade epithelial ovarian, fallopian tube, and primary peritoneal cancer
- Advanced ovarian cancer requiring platinum‑based chemotherapy
The research also explores diagnostic tools like HER2DX to tailor therapy, with an emphasis on preserving fertility and enhancing long‑term survivorship.
Hemic and Lymphatic Diseases
The department’s hematology‑oncology program investigates high‑risk chronic lymphocytic leukemia, testing synergistic regimens that combine a BTK inhibitor, an anti‑CD20 antibody, and a BCL‑2 antagonist to achieve deeper and more durable responses.
- High‑risk chronic lymphocytic leukemia (CLL)
- CLL with 17p deletion or TP53 mutation
- CLL with complex karyotype or unmutated IGHV
These studies target prolonged progression‑free survival and aim to establish new standards of care for patients with adverse genetic profiles.
Neoplasms
A broad portfolio of trials addresses solid tumours beyond the digestive tract, including lung, breast, and rare molecular subtypes, with the goal of validating next‑generation targeted and immunotherapeutic approaches that can improve event‑free and overall survival.
- Metastatic non‑small cell lung cancer, including RET fusion‑positive disease
- Triple‑negative breast cancer
- Hormone‑receptor‑positive, HER2‑negative early breast cancer
- High‑risk lobular breast cancer
- Advanced esophageal adenocarcinoma undergoing organ‑preserving therapy
The trials also incorporate patient‑reported outcomes to assess the impact of treatment on daily living and to guide future therapeutic strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 60 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Leopoldina-Krankenhaus der Stadt Schweinfurt GmbH
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O). | AstraZeneca AB | Phase III | Not Recruiting | Feb 2019 | Apr 2026 |
IMP list
lock Showing 1 of 60 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 6 | Unknown | 2021-02-01 | 2025-12-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.